Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin’s recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil Award-winning research evaluated Nexalin’s DIFS™ 15 mA, 77.5 Hz platform for insomnia symptoms in patients with comorbid anxiety, with the primary reported finding being a significant, durable improvement in sleep quality Independent scientific recognition further strengthens the growing clinical and scientific visibility behind Nexalin’s differentiated, non-invasive frequency-based neurostimulation platform as the Company prepares for product launch in Brazil HOUSTON, TX, June 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that Dr. Victor Fontenelle Bastos de Lima, an investigator on the Company’s recently completed Brazilian clinical study, has received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil. The award recognized research evaluating Nexalin’s proprietary DIFS™ 15 milliamp (mA), 77.5 Hz treatment platform. The award-winning work, titled: “Transcranial Alternating Current Stimulation for Insomnia Symptoms in Patients with Comorbid Anxiety: Preliminary Results from the New Waves Study,” was selected through the Congress’s competitive abstract evaluation process, a scientific distinction granted to a limited number of works presented by early-career investigators. The research is based on Nexalin’s single-center, prospective, clinical trial conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo, in which adults with generalized anxiety disorder and comorbid insomnia received 20 sessions of transcranial alternating current stimulation administered using the Nexalin DIFS™ device at 15 mA and 77.5 Hz. The preliminary results presented at the Congress demonstrated a significant improvement in sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI), observed both at the end of treatment and at follow-up, with large effect sizes. The Young Researcher Award is an academic distinction that recognizes the scientific merit of research conducted by an early-career investigator. It does not constitute an evaluation, endorsement, clearance, or approval of any Nexalin product by any regulatory authority, and is not indicative of the safety, efficacy, or regulatory outcome of the Company’s technology. Nexalin has received approval from ANVISA which serves as the Brazilian equivalent to the FDA, to market, sell and distribute its proprietary Nexalin SYNC medical device for anxiety, depression, and insomnia within Brazil. “We are very proud that research evaluating the Nexalin DIFS™ platform has been recognized with the Young Researcher Award at a respected international scientific congress,” said Mark White, Chief Executive Officer of Nexalin Technology. “This independent recognition by the broader scientific community is another meaningful validation point for our proprietary, non-invasive approach, and it reinforces our belief that Nexalin is developing a fundamentally differentiated and advanced neuro-technology platform, not a ‘me-too’ neurostimulation device. We congratulate Dr. Fontenelle and the entire research team on this well-deserved honor.” Mr. White continued, “We believe this recognition is especially timely as we prepare for product launch in Brazil, where the study was conducted. Independent scientific acknowledgment of this kind helps build awareness and credibility for our technology among clinicians, researchers, and patients in an important international market, and is consistent with our broader strategy of advancing the clinical and scientific foundation behind the DIFS™ platform.” The award-winning research stems from the same Brazilian clinical trial whose successful completion the Company announced on June 10, 2026, and which forms the basis of two clinical abstracts recently accepted for presentation at the 2026 NYC Neuromodulation Conference. Together, these developments reflect the growing scientific visibility of Nexalin’s clinical data across multiple interconnected neuropsychiatric domains, including anxiety, depression, insomnia, and quality of life. “Independent recognition of this kind is meaningful because it reflects engagement with our data by the broader scientific community,” said Dr. David Owens, Chief Medical Officer of Nexalin Technology. “The award-winning analysis focused on improvements in sleep quality, one of several interconnected outcomes in which Nexalin’s platform has shown encouraging data, will add to a growing and consistent body of evidence that supports continued evaluation of our DIFS™ platform.” Unlike many neurostimulation technologies that are based on incremen